EMC3: A 30 kDa Protein as a Potential Drug Target and Biomarker

Target Name: EMC3

NCBI ID: G55831

EMC3

EMC3: A 30 kDa Protein as a Potential Drug Target and Biomarker

EMC3 (endoplasmic reticulum-resident cytoplasmic protein 3) is a 30 kDa protein that is expressed in most tissues and cells of the human body. EMC3 is a unique protein that is characterized by its ability to interact with various cellular signaling pathways, including TOR, PI3K, and NF-kappa-B. Its unique features and subcellular localization have made it an attractive candidate for drug targeting and as a biomarker for various diseases.

Disease-Related Significance

EMC3 has been implicated in several diseases and conditions, including cancer, neurodegenerative diseases, and autoimmune disorders. Its involvement in these diseases has led to theEMC3 as a potential drug target and biomarker.

In cancer, EMC3 has been shown to play a crucial role in cell survival and proliferation. It has been shown to be involved in the regulation of cell cycle, apoptosis, and angiogenesis. Several studies have shown that inhibiting EMC3 can lead to a reduction in cancer cell proliferation and a decrease in tumor growth. This suggests that EMC3 may be an effective target for cancer therapy.

In neurodegenerative diseases, EMC3 has been linked to the progression of neurodegeneration. Its localization to the endoplasmic reticulum and its ability to interact with various signaling pathways make it a potential target for neurodegenerative diseases.

In autoimmune disorders, EMC3 has been shown to play a role in the regulation of immune cell function. It has been implicated in the development of autoimmune diseases such as rheumatoid arthritis and multiple sclerosis. Interrupting EMC3 function may be a potential approach for treating autoimmune disorders.

Potential Therapeutic Strategies

Several potential therapeutic strategies have been proposed for targeting EMC3. These include inhibition of its synthesis, degradation, or function, as well as modulation of its expression levels.

One approach to targeting EMC3 is to inhibit its synthesis by preventing theacylation of its transmembrane domain. This would result in a decrease in the amount of EMC3 available in the cytoplasm and a reduction in its localization to the endoplasmic reticulum.

Another approach is to target EMC3 by modulating its stability or localization to the endoplasmic reticulum. This could be achieved by modifying its stability through changes in its phosphorylation state or by altering its localization through changes in its subcellular localization.

In addition to these approaches, EMC3 can also be targeted by modifying its function by modulating its activity in various cellular signaling pathways. This could include inhibiting its activity in pathways that promote cell survival and proliferation, or modulating its activity in pathways that regulate cell apoptosis.

Conclusion

EMC3 is a 30 kDa protein that has been implicated in several diseases and conditions. Its unique features and subcellular localization have made it an attractive candidate for drug targeting and as a biomarker. The potential therapeutic strategies outlined above demonstrate the promise of EMC3 as a drug target and biomarker. Further research is needed to fully understand its role in disease and to develop effective therapies.

Protein Name: ER Membrane Protein Complex Subunit 3

Functions: Part of the endoplasmic reticulum membrane protein complex (EMC) that enables the energy-independent insertion into endoplasmic reticulum membranes of newly synthesized membrane proteins (PubMed:30415835, PubMed:29809151, PubMed:29242231, PubMed:32459176, PubMed:32439656). Preferentially accommodates proteins with transmembrane domains that are weakly hydrophobic or contain destabilizing features such as charged and aromatic residues (PubMed:30415835, PubMed:29809151, PubMed:29242231). Involved in the cotranslational insertion of multi-pass membrane proteins in which stop-transfer membrane-anchor sequences become ER membrane spanning helices (PubMed:30415835, PubMed:29809151). It is also required for the post-translational insertion of tail-anchored/TA proteins in endoplasmic reticulum membranes (PubMed:29809151, PubMed:29242231). By mediating the proper cotranslational insertion of N-terminal transmembrane domains in an N-exo topology, with translocated N-terminus in the lumen of the ER, controls the topology of multi-pass membrane proteins like the G protein-coupled receptors (PubMed:30415835). By regulating the insertion of various proteins in membranes, it is indirectly involved in many cellular processes (Probable)

The "EMC3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about EMC3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets